XHXin-Hui Huang

Xin-Hui Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin-Hui Huang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Wuhua Guo

    Interventional Department Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China

    2 shared publications
  • Geng Chen

    The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China

    1 shared publication
  • Haijun Yu

    State Key Laboratory of Drug Research, Center of Pharmaceutics Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai China

    1 shared publication
  • Jianhui Lin

    The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China

    1 shared publication
  • Kailiang Zhang

    Interventional Department Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China

    1 shared publication
  • Liman Qiu

    The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China

    1 shared publication

Latest Publications

  • Sequential personalized neoantigen vaccination following first‐line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma

    by Zhixiong Cai, Liman Qiu, Ling Li, Zhenli Li, Kailiang Zhang, Yan Lin, Yang Zhou, Xiuqing Dong, Geng Chen, Rong Xie, et al.

    Hepatocellular carcinoma (HCC) has limited therapeutic options in the advanced stages; although first‐line combinations of transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) and/or programmed cell death protein 1 (PD‐1) inhibitors show promise, their efficacy is constrained by inadequate tumor‐specific T‐cell infiltration. To address this limitation, we conducted an investigator‐initiated, single‐center clinical trial (ChiCTR2300067818) evaluating the safety, feasibility, and preliminary efficacy of sequential personalized neoantigen vaccination following TACE plus TKI/PD‐1‐based therapy in patients with advanced HCC. Whole‐exome and transcriptome sequencing identified patient‐specific neoantigens, which were synthesized as long peptides and formulated with dual adjuvants for subcutaneous administration. Among 10 initially enrolled patients, 4 received personalized vaccination after comprehensive screening, with 2 patients (N03 and N04) completing the full 8‐injection vaccination regimen. Sequential neoantigen vaccination demonstrated excellent safety profiles, with only mild injection‐site reactions observed. Both patients achieved partial response following vaccination. Interferon‐gamma Enzyme‐Linked ImmunoSpot assays confirmed robust neoantigen‐specific responses against multiple peptide pools in both patients. Dynamic monitoring revealed that serum alpha‐fetoprotein and Des‐gamma‐carboxy prothrombin levels correlated with clinical responses, declining significantly during vaccination. These findings demonstrate that sequential personalized neoantigen vaccination following first‐line TACE‐based therapy is safe, feasible, and capable of inducing potent tumor‐specific immune responses, supporting further investigation in larger clinical trials.


  • Open Access

    Ultra‐Large Spontaneous Portosystemic Shunt is Correlated With a Higher Hepatic Venous Pressure Gradient and Increased Risk of Hepatic Encephalopathy

    by Xiao-Juan Lei, Yu-Bing Jiao, Xin-Hui Huang, Sheng-Zhao Li, Qiao Ke, Wu-Hua Guo

    Background: Spontaneous portosystemic shunts (SPSSs) frequently develop in individuals with cirrhosis. However, their clinical impact on the hepatic venous pressure gradient (HVPG) and liver function remains complex and a subject of ongoing debate. This retrospective study evaluated the relationship between SPSS diameter, particularly ultra‐large SPSS, and HVPG, liver dysfunction, and their predictive value in patients with cirrhosis. Methods: A retrospective study was conducted on 90 cirrhotic patients. The patients were categorized into three groups: no SPSS (none or φ < 3 mm), small SPSS (3 ≤ φ < 8 mm), and large SPSS ( φ ≥ 8 mm). The large SPSS group was further stratified into large (8 ≤ φ < 14.5 mm) and ultra‐large ( φ ≥ 14.5 mm) subgroups based on a receiver operating characteristic (ROC)−derived cutoff for hepatic encephalopathy (HE). Clinical parameters, HVPG, and vascular diameters were analyzed. Results: The large SPSS group had higher total bilirubin and a higher incidence of HE than the no SPSS group. Within the large SPSS cohort, the ultra‐large subgroup (≥ 14.5 mm) demonstrated significantly worse liver function (lower albumin, higher bilirubin, prolonged PT, increased INR, and poorer Child–Pugh/MELD scores), a higher proportion of Child–Pugh Class C, and elevated HVPG values (18.7 vs. 16.6 mmHg, p = 0.03) compared to the large subgroup. Critically, SPSS diameter showed a significant positive correlation with HVPG ( R = 0.314, p = 0.013). The incidence of HE was also significantly higher in the ultra‐large subgroup (55.52% vs. 11%, p = 0.001). Conclusions: The portal pressure‐lowering effect of SPSS does not correlate linearly with its diameter, exhibiting a threshold‐dependent attenuation as shunt size exceeds 14.5 mm. This cutoff may serve as a predictor of increased risk for HE and liver dysfunction in cirrhosis, supporting its potential role in clinical risk stratification and decision‐making for cirrhosis patients with SPSS.